Regeneron nelle notizie
Medicina, scienza, salute, globale
Tamtam ha trovato 20 articoli recenti su Regeneron.
- Regeneron price target raised to $950 from $900 at JPMorgan
- Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Gets Price Target Bump from Truist Financial
- Regeneron sees nearly $0.18 per share earnings headwind in Q3
- Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day
- Regeneron, Sanofi deepen antibody collaboration with expanded alliance
- Regeneron: The Easy Money Has Been Made (Rating Downgrade) (NASDAQ:REGN)
- Sanofi Deepens 20-Year Drug Development Pact With Regeneron, Pledges Up to $8 Billion
- EASD 2026: Regeneron’s muscle preserver shows benefit at lower doses
- #EASD26: Regeneron sees a future combining its obesity drug with lipid-lowering therapy
- Regeneron Phase II trial confirms trevogrumab halves muscle loss
- Why Regeneron (REGN) Stock Is Trading Lower Today
- Regeneron drug said to cut muscle loss when combined with Novo's semaglutide (REGN:NASDAQ)
- Regeneron And Sanofi Announce A Win-Win Collaboration Expansion (NASDAQ:REGN)
- Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D
- Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies - Slideshow (NASDAQ:REGN) 2026-10-01
- #EASD26: Regeneron’s antibody helps patients regain muscle after stopping GLP-1 therapy
- Sanofi and Regeneron expand global alliance
- Sanofi forges new $8bn pact with Regeneron
- Sanofi, Regeneron broaden alliance to find their next Dupixent
- Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor
Articoli raccolti da Tamtam e conservati quando riguardano l'azienda, dal più recente. Ognuno rimanda alla sua fonte.
Vendi ad aziende come Regeneron?
Tamtam trova le aziende in linea con il tuo cliente ideale, analizza ogni account e ti dice chi contattare e quando.
Trova aziende simili